OTC SUPPLEMENTAL APPLICATIONS WILL REMAIN UNDER PRIMARY PURVIEW OF NEW DRUG REVIEW DIVISIONS: FDAers SEIFE, TEMPLE AND BILSTAD EXPLAIN Rx-TO-OTC